A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

  • Guillem Clot
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Pedro Jares
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Eva Giné
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Alba Navarro
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Cristina Royo
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Magda Pinyol
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • David Martín-Garcia
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Santiago Demajo
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Blanca Espinet
    Pathology Department and
  • Antonio Salar
    Hematology Department, IMIM-Hospital del Mar, Barcelona, Spain;
  • Ana Ferrer
    Hematology Department, IMIM-Hospital del Mar, Barcelona, Spain;
  • Ana Muntañola
    Servei d'Hematologia, Hospital Mútua de Terrassa, Terrassa, Spain;
  • Marta Aymerich
    Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain;
  • Hilka Rauert-Wunderlich
    Institute of Pathology, University of Würzburg, Würzburg, Germany;
  • Elaine S. Jaffe
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Joseph M. Connors
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
  • Randy D. Gascoyne
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
  • Jan Delabie
    Department of Pathology, Toronto General Hospital, Toronto, ON, Canada;
  • Armando López-Guillermo
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • German Ott
    Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; and
  • George W. Wright
    Comprehensive Cancer Center Mainfranken, Würzburg, Germany;
  • Louis M. Staudt
    Comprehensive Cancer Center Mainfranken, Würzburg, Germany;
  • Andreas Rosenwald
    Institute of Pathology, University of Würzburg, Würzburg, Germany;
  • David W. Scott
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
  • Lisa M. Rimsza
    Department of Pathology, Mayo Clinic, Scottsdale, AZ
  • Sílvia Beà
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
  • Elías Campo
    Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;

抄録

<jats:title>Key Points</jats:title> <jats:p>A new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.</jats:p>

収録刊行物

  • Blood

    Blood 132 (4), 413-422, 2018-07-26

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ